Physician profile
Robert Kelly
NPI 1437140860
$1,629.58
in general payments reported to CMS, 2019-2025
20 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $84.09 · 2021: $99.20 · 2022: $376 · 2023: $428 · 2024: $220 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $414.81 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $224.40 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $147.88 | 2019-2025 | Rocklatan, Argos |
| Regeneron Healthcare Solutions, INC. | $141.80 | 2019-2025 | Eylea Hd, Eylea |
| Sun Pharmaceutical Industries INC. | $121.79 | 2019-2025 | Cequa |
| New World Medical,INC. | $82.19 | 2022-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Rayner Intraocular Lenses Limited | $74.55 | 2022-2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $66.19 | 2023-2025 | Syfovre |
| Abbvie INC. | $63.16 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $54.09 | 2019 | |
| Allergan, INC. | $39.99 | 2019-2022 | |
| Horizon Therapeutics Plc | $33.13 | 2022 | |
| Optos, INC. | $28.41 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.63 | 2019 | |
| Abbott Laboratories | $23.45 | 2024 | Perclose Prostyle |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.30 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $20.64 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $18.30 | 2021 | |
| Shire North American Group INC | $15.56 | 2019 | |
| Ocular Therapeutix, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.